Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

[In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: multicenter national study GEIH-REIPI-Ab 2010].

Fernández-Cuenca F, Tomás-Carmona M, Caballero-Moyano F, Bou G, Martínez-Martínez L, Vila J, Pachón J, Cisneros JM, Rodríguez-Baño J, Pascual A; grupo del proyecto GEIH-REIPI-Ab 2010.

Enferm Infecc Microbiol Clin. 2013 Jan;31(1):4-9. doi: 10.1016/j.eimc.2012.06.010. Epub 2012 Aug 29. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2013 May;31(5):353. Pizarraya, Antonio Gutiérrez [added]; Marquez Vacaro, Juan Antonio [added]; Montero, José Garnacho [added].

PMID:
22939566
2.

[Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000)].

Fernández-Cuenca F, Pascual A, Ribera A, Vila J, Bou G, Cisneros JM, Rodríguez-Baño J, Pachón J, Martínez-Martínez L; Grupo de Estudio de Infección Hospitalaria.

Enferm Infecc Microbiol Clin. 2004 May;22(5):267-71. Spanish.

PMID:
15207117
3.

In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.

Song JY, Kee SY, Hwang IS, Seo YB, Jeong HW, Kim WJ, Cheong HJ.

J Antimicrob Chemother. 2007 Aug;60(2):317-22. Epub 2007 May 31.

PMID:
17540672
4.

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.

Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P.

Ann Clin Microbiol Antimicrob. 2009 May 21;8:18. doi: 10.1186/1476-0711-8-18.

5.

Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU.

Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC.

Diagn Microbiol Infect Dis. 2011 Jul;70(3):380-6. doi: 10.1016/j.diagmicrobio.2011.03.003. Epub 2011 May 10.

PMID:
21558048
6.

Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).

Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, Towner KJ, Livermore DM, Woodford N.

J Antimicrob Chemother. 2002 Mar;49(3):479-87.

PMID:
11864948
7.

In vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin- or tigecycline-resistant isolates.

Peck KR, Kim MJ, Choi JY, Kim HS, Kang CI, Cho YK, Park DW, Lee HJ, Lee MS, Ko KS.

J Med Microbiol. 2012 Mar;61(Pt 3):353-60. doi: 10.1099/jmm.0.036939-0. Epub 2011 Oct 20.

PMID:
22016557
8.

Antimicrobial susceptibility patterns of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin, and tigecycline.

Somily AM, Absar MM, Arshad MZ, Al Aska AI, Shakoor ZA, Fatani AJ, Siddiqui YM, Murray TS.

Saudi Med J. 2012 Jul;33(7):750-5.

PMID:
22821309
9.

In vitro activities of rifampin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii.

Dong X, Chen F, Zhang Y, Liu H, Liu Y, Ma L.

J Antibiot (Tokyo). 2014 Sep;67(9):677-80. doi: 10.1038/ja.2014.99. Epub 2014 Aug 6.

PMID:
25095805
10.

[Susceptibility pattern of Acinetobacter baumannii clinical isolates in Madrid vs. Hong Kong].

García-Peñuela E, Aznar E, Alarcón T, López-Brea M.

Rev Esp Quimioter. 2006 Mar;19(1):45-50. Spanish.

11.

In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Scheetz MH, Qi C, Warren JR, Postelnick MJ, Zembower T, Obias A, Noskin GA.

Antimicrob Agents Chemother. 2007 May;51(5):1621-6. Epub 2007 Feb 16.

12.

In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.

Deveci A, Coban AY, Acicbe O, Tanyel E, Yaman G, Durupinar B.

J Chemother. 2012 Oct;24(5):247-52. doi: 10.1179/1973947812Y.0000000029.

PMID:
23182043
14.
15.

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

Liu JW, Wang LS, Cheng YJ, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Chuang YC, Lin HC, Shi ZY, Kung HC, Huang CH, Tsao SM, Lu CT, Liao CH, Hsueh PR.

Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S188-91. doi: 10.1016/S0924-8579(08)70026-8.

PMID:
19013353
16.

In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.

Housman ST, Hagihara M, Nicolau DP, Kuti JL.

J Antimicrob Chemother. 2013 Oct;68(10):2296-304. doi: 10.1093/jac/dkt197. Epub 2013 May 24.

PMID:
23710070
17.

A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital.

Maraki S, Mantadakis E, Mavromanolaki VE, Kofteridis DP, Samonis G.

Infect Chemother. 2016 Sep;48(3):190-198. doi: 10.3947/ic.2016.48.3.190. Epub 2016 Sep 9.

18.

Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia.

Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D.

Int J Antimicrob Agents. 2008 Jul;32(1):29-32. doi: 10.1016/j.ijantimicag.2008.02.016. Epub 2008 Jun 6.

PMID:
18539006
19.

In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore.

Lim TP, Tan TY, Lee W, Sasikala S, Tan TT, Hsu LY, Kwa AL.

PLoS One. 2011 Apr 21;6(4):e18485. doi: 10.1371/journal.pone.0018485.

20.

Supplemental Content

Support Center